Clinical Trials · NCT04065165
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
- Phase
- Phase 3
- Recruitment status
- Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Enrollment
- 0
- Start date
- Apr 2020
- Locations
- See registry
- Primary endpoint
- Number of bowel movements (BMs)